Published in J Clin Oncol on June 14, 2010
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Network-based stratification of tumor mutations. Nat Methods (2013) 3.12
DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 2.70
A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst (2012) 2.07
Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst (2014) 2.06
The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer (2011) 1.71
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med (2013) 1.62
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst (2014) 1.58
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol (2013) 1.55
curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford) (2013) 1.40
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
BRCAness revisited. Nat Rev Cancer (2016) 1.38
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol (2011) 1.31
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst (2014) 1.24
Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol (2010) 1.17
Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem (2012) 1.17
Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest (2013) 1.17
Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol (2010) 1.14
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res (2010) 1.08
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol (2011) 1.06
BRCAness: finding the Achilles heel in ovarian cancer. Oncologist (2012) 1.05
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res (2011) 1.03
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res (2014) 1.03
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer (2013) 1.03
The 'dnet' approach promotes emerging research on cancer patient survival. Genome Med (2014) 1.01
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses. Biochim Biophys Acta (2014) 1.01
BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One (2012) 0.99
The relative efficiency of homology-directed repair has distinct effects on proper anaphase chromosome separation. Nucleic Acids Res (2011) 0.97
'BRCAness' and its implications for platinum action in gynecologic cancer. Anticancer Res (2014) 0.96
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res (2010) 0.95
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol (2012) 0.94
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics (2012) 0.93
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol (2013) 0.92
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol (2014) 0.90
PARP inhibitors: the race is on. Br J Cancer (2016) 0.90
Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet (2012) 0.90
BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2. Neoplasia (2013) 0.89
Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics (2014) 0.89
Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am (2012) 0.88
COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget (2015) 0.88
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res (2014) 0.86
New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol (2013) 0.86
Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs (2012) 0.85
Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. J Natl Cancer Inst (2012) 0.85
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One (2011) 0.84
Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol (2012) 0.83
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. Oncotarget (2015) 0.83
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov (2016) 0.82
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget (2014) 0.82
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer (2014) 0.81
Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients. Hered Cancer Clin Pract (2016) 0.81
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol (2014) 0.81
PARP inhibitors. Hered Cancer Clin Pract (2015) 0.81
Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. J Ovarian Res (2010) 0.80
Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes. BMC Genomics (2015) 0.80
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. JAMA (2012) 0.80
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res (2016) 0.79
Algorithmic methods to infer the evolutionary trajectories in cancer progression. Proc Natl Acad Sci U S A (2016) 0.79
Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol (2015) 0.79
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med (2016) 0.79
Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS One (2013) 0.79
Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain. ACS Chem Biol (2015) 0.78
Extracting a low-dimensional description of multiple gene expression datasets reveals a potential driver for tumor-associated stroma in ovarian cancer. Genome Med (2016) 0.78
3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents. Oncotarget (2015) 0.77
Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers. Int J Breast Cancer (2011) 0.77
Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. Int J Gynecol Cancer (2013) 0.77
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol (2016) 0.77
Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes. Acta Pharmacol Sin (2015) 0.77
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study. Cell Cycle (2015) 0.76
Integrating cancer genomic data into electronic health records. Genome Med (2016) 0.76
Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Fam Cancer (2016) 0.76
Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget (2016) 0.76
Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res (2012) 0.76
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther (2013) 0.76
Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol (2016) 0.75
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors? Front Pharmacol (2012) 0.75
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn (2016) 0.75
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
Pathway-Informed Classification System (PICS) for Cancer Analysis Using Gene Expression Data. Cancer Inform (2016) 0.75
Patient-derived tumour xenografts for breast cancer drug discovery. Endocr Relat Cancer (2016) 0.75
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer. PLoS One (2016) 0.75
Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res (2017) 0.75
Unexpected long-term survival in a BRCA2 patient with metastatic carcinosarcoma associated with tamoxifen. Gynecol Oncol Case Rep (2013) 0.75
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. J Ovarian Res (2016) 0.75
Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract (2016) 0.75
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer (2017) 0.75
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem (2016) 0.75
Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol Clin Oncol (2017) 0.75
IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. Stat Biosci (2016) 0.75
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. NPJ Syst Biol Appl (2017) 0.75
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Cancer of the ovary. N Engl J Med (2004) 11.21
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol (2002) 6.69
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
The Fanconi anaemia/BRCA pathway. Nat Rev Cancer (2003) 5.89
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov (2005) 4.61
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
A paradigm for class prediction using gene expression profiles. J Comput Biol (2002) 3.64
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res (2007) 2.58
Classification of microarrays to nearest centroids. Bioinformatics (2005) 2.56
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res (2007) 2.25
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst (2002) 1.87
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res (2000) 1.83
Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol (2008) 1.73
Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: the 3' ends justify the means. Mutat Res (2000) 1.71
Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol (2005) 1.64
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res (1996) 1.47
Training nu-support vector classifiers: theory and algorithms. Neural Comput (2001) 1.40
Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst (2002) 1.31
Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol (1999) 1.18
Mechanisms of drug resistance in ovarian cancer. Cancer (1993) 1.06
Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics (2008) 1.04
Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol (2003) 1.01
Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res (2003) 0.99
Optimality driven nearest centroid classification from genomic data. PLoS One (2007) 0.98
Treating cancer by targeting a weakness. N Engl J Med (2005) 0.90
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 9.31
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A (2005) 3.93
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res (2002) 3.64
ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev (2004) 3.44
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res (2003) 3.30
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
Granulosa cell tumor of the ovary. J Clin Oncol (2003) 2.70
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
Effect of obesity on survival in epithelial ovarian cancer. Cancer (2006) 2.52
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Is the easier way ever the better way? J Clin Oncol (2011) 2.41
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol (2013) 2.28
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol (2004) 2.25
The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet (2005) 2.23
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med (2011) 2.16
Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res (2011) 2.14
Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res (2007) 2.14
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol (2008) 2.14
Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol (2009) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood (2004) 2.08
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol (2002) 1.96
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 1.95
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther (2006) 1.88
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res (2006) 1.82
Phase II trials in journal of clinical oncology. J Clin Oncol (2009) 1.78
Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One (2012) 1.76
Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol (2008) 1.73
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol (2006) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin Chem Lab Med (2005) 1.68
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res (2009) 1.66
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol (2006) 1.65
Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol (2005) 1.64
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol (2006) 1.64
BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol (2005) 1.63
Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol (2005) 1.62
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol (2004) 1.60
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res (2013) 1.54
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol (2011) 1.53
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res (2008) 1.48
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46
Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol (2012) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.37
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol (2010) 1.37
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36